top of page

Avani Mody, Ph.D.

Research Scientist

  • LinkedIn
Avani Mody_edited.jpg
Avani Mody Bio


Dr. Avani A. Mody is a distinguished biomedical scientist with a passion for innovation and a
proven track record in the field of molecular biology. She brings more then 10 years of expertise
to the realm of clinical molecular biology and therapeutics development. At Cure Science, Dr. Mody is involved in drug development, setting up GLP compliance and assisting in business development.

With a Ph.D. in Biomedical Science from the University of North Texas HSC, Dr. Mody has
showcased her proficiency in molecular techniques, developing clinical diagnostic workflow, and
nucleic acid manipulation. Her extensive background includes leadership roles, most recently as
a Scientist (Study Director) at Absorption System, a CRO specializing in retina, gene therapy, and
glaucoma. Previously, as a graduate research scientist at the North Texas Eye Research
Institute, Dr. Mody led a gene therapy project focused on lowering intra ocular pressure in
primary open angle glaucoma model. With a history of leading multiple projects during her
tenure as a Graduate Research Assistant at the University of North Texas HSC, Dr. Mody's
contributions extended to diverse areas such as microbiology, developing diagnostic products
for infectious disease, signal transduction, neuroscience and ophthalmology. Dr. Mody has
presented her research findings at national and international conferences. Her dedication to the
field is evident in her numerous peer-reviewed publications, contributing valuable insights to the
scientific community.

Beyond her professional achievements, Dr. Mody is a member of 500 Women Scientists, Women
in Bio and AWIS. Her multifaceted interests include open water swimming, yoga, volunteering,
hikes, and badminton. She has also organized and participated in fundraisers for cancer
patients, cancer research, vision screens for kids and education for underprivilege children.

Most Recent Publications

1. Avani A. Mody, J. Cameron Millar, Abbot F. Clark; ID1 and ID3 are Negative Regulators of TGFβ2-Induced Ocular Hypertension and Compromised Aqueous Humor Outflow Facility in Mice. Invest. Ophthalmol. Vis. Sci. 2021;62(6):3.

2. Avani A. Mody, Robert J. Wordinger, Abbot F. Clark; Role of ID Proteins in BMP4 Inhibition of Profibrotic Effects of TGF-β2 in Human TM Cells. Invest. Ophthalmol. Vis. Sci. 2017;58(2):849-859.

3. Mody, Avani A., et al. "Protective effect of ID protein on TGFβ2 induced fibrosis in human trabecular meshwork cells: implication for developing a glaucoma therapy." (2017).

4. Effects of TGFβ2 and BMP4 Downstream Targets ID1 and ID3 in Trabecular Meshwork: Implications In Lowering IOP - ProQuest. (n.d.).

5. Mody, A. A., A. F. Clark, and R. J. Wordinger. "ID1 and ID3 downstream transcription regulators in BMP4 signaling inhibits TGF beta 2 induced fibrosis in TM cells." MOLECULAR BIOLOGY OF THE CELL. Vol. 27. 8120 WOODMONT AVE, STE 750, BETHESDA, MD 20814-2755 USA: AMER SOC CELL BIOLOGY, 2016.

6. Avani Mody, Abbot F Clark, Robert J Wordinger, none; BMP4 induced ID proteins protect TM from glaucomatous effects of TGFβ2. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):3297.

7. Mao, W., Liu, Y., Mody, A. A., Montecchi-Palmer, M., Wordinger, R. J., & Clark, A. F. (2012, December 1). Characterization of a spontaneously immortalized bovine trabecular meshwork cell line. Experimental Eye Research.

8. Rahman, M., Zhang, Z., Mody, A. A., Su, D., & Das, H. K. (2012, April 1). Intraperitoneal injection of JNK-specific inhibitor SP600125 inhibits the expression of presenilin-1 and Notch signaling in mouse brain without induction of apoptosis. Brain Research.

9. Raut, S., Heck, A., Vishwanatha, J. K., Sarkar, P., Mody, A. A., Luchowski, R., Gryczyński, Z., & Gryczyński, I. (2011, March 1). Fluorescent properties of antioxidant cysteine ABZ analogue. Journal of Photochemistry and Photobiology B: Biology.
bottom of page